Day: July 25, 2021

Rapid reduction and sustained normalization of heparan sulfate in CSF demonstrated robust and durable CNS activity with intravenous administration, and enhanced peripheral activity with reductions in urine and serum heparan sulfate after switching from standard-of-care idursulfaseGlobal Impression of Change scales data suggested clinical improvement in overall MPS II symptoms, cognitive abilities, behavior, and physical abilitiesExploratory biomarker data demonstrated reductions in CSF lysosomal lipid biomarkers that are consistent with improved lysosomal function; and high variability in exploratory biomarker Nf-L was observed pre- and post-treatmentSafety profile with up to 43 weeks of dosing was consistent with standard of care enzyme replacement therapy with infusion-related reactions being the most frequently observed adverse...

In week 29 Kvika banki hf. („Kvika“ or „the bank“) purchased 10,000,000 of its own shares at the purchase price 238,600,000 ISK. See further details below:Date Time No. of shares purchased Share price (rate) Purchase price19.7.2021 09:39:51 1,000,000 24.400 24,400,00019.7.2021 10:20:45 1,000,000 24.400 24,400,00020.7.2021 09:59:32 1,000,000 24.000 24,000,00020.7.2021 10:25:01 1,000,000 24.000 24,000,00021.7.2021 09:41:29 1,000,000 23.800 23,800,00021.7.2021 10:18:49 1,000,000 23.800 23,800,00022.7.2021 09:47:52 1,000,000 23.700 23,700,00022.7.2021 11:30:44 1,000,000 23.550 23,550,00023.7.2021 09:41:40 1,000,000 23.475 23,475,00023.7.2021 09:55:57 1.,000,000 23.475 23,475,000Total   10,000,000   238,600,000The trade is in accordance with Kvika’s buyback programme, announced on 16 July 2021 and...

The preliminary results for the second quarter of 2021 indicate that net earnings before tax will amount to ISK 3,550 – 3,650 million. TM’s combined ratio at a historical low and return on financial assets above expectations TM’s combined ratio was approximately 80.8% during the second quarter and 91.5% during the first half of 2021. The return on financial assets was 3.6% during the second quarter. TM’s net earnings before tax during the second quarter were approximately ISK 1,870 million. Solid growth in net fee and commission income and net interest income during the second quarter Net fee and commission income increased by roughly 20% between quarters and amounted to ISK 2,046 million during the second quarter, while net interest income amounted to ISK 1,156 million. Net investment income during the quarter amounted...